Malaria on the Thai-Burmese border: treatment of 5192 patients with mefloquine-sulfadoxine-pyrimethamine
- PMID: 3325187
- PMCID: PMC2491097
Malaria on the Thai-Burmese border: treatment of 5192 patients with mefloquine-sulfadoxine-pyrimethamine
Abstract
Multidrug-resistant falciparum malaria is a major health problem along the Thai-Burmese border. From July 1985 until December 1986 a total of 5192 patients with falciparum malaria (1734 males, 3458 females) from this area were given supervised treatment with the combination mefloquine-sulfadoxine-pyrimethamine (MSP). The radical cure rate, assessed 21 days after drug administration, was 98.4% for the first 1975 patients, and 98.8% when assessed at 28 days for the remaining 3217 patients. In 3.8% of cases, parasites were still detected in peripheral blood smears on day 7 after treatment but this had fallen to 0.27% by day 9. Adverse reactions among the first 1975 patients were: vertigo (7.5% of patients), vomiting (5.8%), epigastric pain (0.6%), and transient confusional state (one case). MSP is an effective and well-tolerated drug for the treatment of drug-resistant falciparum malaria; however, delayed parasite clearance may give a false impression of RII resistance.
Similar articles
-
Double-blind dose finding study of mefloquine-sulfadoxine-pyrimethamine in children with acute falciparum malaria.Trans R Soc Trop Med Hyg. 1988;82(4):538-40. doi: 10.1016/0035-9203(88)90496-8. Trans R Soc Trop Med Hyg. 1988. PMID: 3076709 Clinical Trial.
-
A phase I clinical trial of mefloquine in Brazilian male subjects.Bull World Health Organ. 1983;61(5):809-14. Bull World Health Organ. 1983. PMID: 6360400 Free PMC article. Clinical Trial.
-
Prospective double-blind trial of two different doses of mefloquine plus pyrimethamine-sulfadoxine compared with pyrimethamine-sulfadoxine alone in the treatment of falciparum malaria.Bull World Health Organ. 1985;63(4):731-7. Bull World Health Organ. 1985. PMID: 3910296 Free PMC article. Clinical Trial.
-
[Treatment of Plasmodium falciparum malaria in Africa (except cerebral malaria)].Med Trop (Mars). 1990 Jan-Mar;50(1):103-8. Med Trop (Mars). 1990. PMID: 2195275 Review. French.
-
New drugs and their potential use against drug-resistant malaria.Ann Ist Super Sanita. 1985;21(3):327-36. Ann Ist Super Sanita. 1985. PMID: 3914850 Review. No abstract available.
Cited by
-
Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.Drugs. 1993 Mar;45(3):430-75. doi: 10.2165/00003495-199345030-00009. Drugs. 1993. PMID: 7682911 Review.
-
The story of artesunate-mefloquine (ASMQ), innovative partnerships in drug development: case study.Malar J. 2013 Feb 21;12:68. doi: 10.1186/1475-2875-12-68. Malar J. 2013. PMID: 23433060 Free PMC article.
-
Treatment of malaria--1990.Drugs. 1990 Feb;39(2):160-89. doi: 10.2165/00003495-199039020-00002. Drugs. 1990. PMID: 2183998 Review.
-
Primaquine: the risks and the benefits.Malar J. 2014 Nov 3;13:418. doi: 10.1186/1475-2875-13-418. Malar J. 2014. PMID: 25363455 Free PMC article. Review.
-
Enhancing the antimalarial activity of artesunate.Parasitol Res. 2020 Sep;119(9):2749-2764. doi: 10.1007/s00436-020-06786-1. Epub 2020 Jul 7. Parasitol Res. 2020. PMID: 32638101 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials